A Canadian multicenter trial assessing memory and executive functions in patients with schizophrenia spectrum disorders treated with olanzapine

Journal of Clinical Psychopharmacology

Volumn 23, Issue 4, 2003, Pages 400-404

  Stip, Emmanuel ^a   Remington, Gary J ^b   Dursun, Serdar M ^c   Reiss, Jeffrey P ^d   Rotstein, Edward ^e   MacEwan, Gordon William ^f   Chokka, Pratap R ^g   Jones, Barry ^e,h   Dickson, Ruth A ⁱ  

^a CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY OF MANITOBA   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g Department of Psychiatry   (Canada)

^h ELI LILLY AND COMPANY   (United States)

ⁱ UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; AKATHISIA; APPETITE DISORDER; ARTICLE; ASTHENIA; CANADA; CLINICAL TRIAL; COGNITION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HUMAN; INSOMNIA; LEARNING; MAJOR CLINICAL STUDY; MALE; MEMORY; MULTICENTER STUDY; OPEN STUDY; PARKINSONISM; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOPHARMACOTHERAPY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; VERTIGO; WEIGHT GAIN; XEROSTOMIA;

ACOUSTIC STIMULATION; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CANADA; COGNITION; FEMALE; HUMANS; MALE; MEMORY; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PIRENZEPINE; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR PERFORMANCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; VERBAL LEARNING; WORD ASSOCIATION TESTS;

EID: 0042634380     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000085414.08426.8f     Document Type: Article

References (28)

1. Stip E. Olanzapine and Cognition. In: Tran PV, Bymaster FP, Tye N, et al, eds. Olanzapine (Zyprexa): A Novel Antipsychotic. Philadelphia: Lippincott Williams & Wilkins Healthcare; 2001:401-415.
2. Purdon S, Jones B, Chouinard G, et al. Neuropsychological change in early phase schizophrenia during twelve months of treatment with olanzapine, risperidone or haloperidol. Arch Gen Psychiatry. 2000;57:249-258.
3. Mahmoud R, Harvey PD, Meltzer HY, et al. Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizo-affective disorder. Schizophr Res. 2001;49(suppl 1):236-237.
4. Stip E, Lussier I. The effect of risperidone on cognition in patients with schizophrenia. Can J Psychiatry. 1996;41(suppl 2):S35-S40.
5. Harvey PD, Meltzer HY, Romano S. Improvement in cognition following a switch to open-label ziprasidone from olanzapine, risperidone and conventional antipsychotics. Int J Neuropsychopharmacol. 2000;3(suppl. 1):161.
6. Purdon S, Labelle A, Boulay L. Neuropsychological change in schizophrenia after 6 weeks of clozapine. Schizophr Res. 2001;48:57-67.
7. Stip E, Lussier I, Babaï M, et al. Seroquel and cognitive improvement in patient with schizophrenia. Biol Psychiatry. 1996;40:434-435.
8. Purdon S, Malla A, Labelle A, et al. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci. 2001;26:137-149.
9. Kuperberg G, Heckers S. Schizophrenia and cognitive function. Curr Opin Neurobiol. 2000;10:205-210.
10. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321-330.
11. Penades P, Gasto C, Boget T, et al. Deficit in schizophrenia: the relationship between negative symptoms and neurocognition. Compr Psychiatry. 2001;42:64-69.
12. Rey A. L'examen clinique en psychologie. Paris: Presses Universitaires de France; 1964.
13. Crawford J, Howell D, Garthwaite P. Payne and Jones revisited: estimating the abnormality of test score differences using a modified paired samples t test. J Clin Exp Neuropsychol. 1998;20:898-905.
14. Spreen O, Benton AL. Neurosensory Centre Comprehensive Examination for Aphasia (NCCEA). Revised ed. Victoria, Australia: University of Victoria Neuropsychology Laboratory; 1977.
15. Robert PH, Thauby V, Migneco I, et al. Différenciation de sous-types de troubles schizophréniques en fonction des performances au test de fluence verbale. Encéphale. 1996;23:435-442.
16. Battig WF, Montague WE. Category norms for verbal items in 56 categories: a replication and extension of the Connecticut category norms. J Exp Psychol Monogr. 1969;80(3, Pt 2).
17. Reitan R. Trail-Making Test: Manual for Administration and Scoring. Tucson, Ariz: Reitan Neuropsychological Laboratory; 1992.
18. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS). Psychol Rep. 1962;10:799-812.
19. Guy W. The Clinical Global Impression Scale. In: ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health, Education and Welfare; 1976 (Publication No. (ADM) 76-338).
20. Wechsler D. Wechsler Adult Intelligence Scale ± Revised. San Antonio, TX: Harcourt Brace; 1982.
21. Keefe RS, Silva SG, Perkins DO, et al. The effect of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull. 1999;25:201-222.
22. Cuesta MJ, Peralta V, Zarzuela A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophr Res. 2001;48:17-28.
23. Wilson BA, Watson PC, Baddeley AD, et al. Improvement or simply practice? The effects of twenty repeated assessments on people with and without brain injury. J Int Neuropsychol Soc. 2000;6:469-479.
24. Aleman A, Hijman R, de Haan EH, et al. Memory impairment in schizophrenia: a meta-analysis. Am J Psychiatry. 1999;156:1358-1366.
25. Green MF, Nuechterlein KH. Backward masking performance as an indicator of vulnerability to schizophrenia. Acta Psychiatr Scand. 1999;395(suppl):34-40.
26. Stip E. Quetiapine and cognitive improvement in a patient with schizophrenia. J Clin Psychiatry. 1999;60(suppl 23):27-28.
27. Stip E. Discriminant cognitive factors according to treatment response and to antipsychotic drugs in patients with schizophrenia: issues on practice effect, dosing, D2 occupancy, and procedural learning. Eur Neuropsychopharmacol. 2001;11(suppl 3):134-135.
28. Bedard MA, Scherer H, Stip E, et al. Procedural learning in schizophrenia: further consideration on the deleterious effect of neuroleptics. Brain Cogn. 2000;43:31-39.